R&D channel feed – Endpoints News

R&D channel feed

Intellia gets FDA clearance to start hereditary angioedema gene editing trial in US

3 years ago

MorphoSys chops back again, this time cutting preclinical efforts in late-stage push

3 years ago

Scoop: Ascletis' NASH subsidiary scraps US PhII trial in favor of China

3 years ago

Novo Nordisk touts expansion in Boston, cuts about 100 jobs in two other US cities

3 years ago

A radioactive prostate cancer therapy is a last lifeline for patients. Novartis can't make enough of it

3 years ago

Keytruda hits one primary endpoint for use before and after surgery in lung cancer

3 years ago

G1 Therapeutics delays PhIII readout of lead drug — will cut 30% of staff, CFO to exit

3 years ago

Ready to turn a new page, Landos Biopharma offloads former lead program to founder

3 years ago

Pfizer was warned of Lyme study problems months ago, trial research startup's CEO tells employees

3 years ago

Celldex fleshes out case for Xolair challenger in chronic hives

3 years ago

Merck’s Keytruda fails more prostate and lung cancer PhIII trials

3 years ago

Theravance cuts 17% of staff, JAK inhibitor program

3 years ago

Decades after breakthrough, scientists still puzzling over mRNA delivery

3 years ago

Suffering CNS player flips another losing hand in a last PhII gamble and calls for the axe

3 years ago

AstraZeneca expands Canada R&D work, to add 500 jobs

3 years ago

State attorneys general sue FDA over abortion pill access restrictions

3 years ago

Axsome says FDA wants more data for Alzheimer’s agitation label expansion, but readout to come sooner

3 years ago

Ahead of FDA decision, Blueprint puts out full data for expanded Ayvakit label

3 years ago

Kura Oncology drops multiple clinical programs for J&J-discovered tipifarnib

3 years ago

Galapagos goes 0-for-3 on inflammation program as it cuts an early-stage candidate

3 years ago

Novartis retreat from NASH takes down $80M alliance with Pliant Therapeutics

3 years ago

Nektar’s latest PhII flop threatens to unravel $400M-plus deal with Eli Lilly

3 years ago

Bristol Myers expands footprint in India with drug development and IT center

3 years ago

Moderna predicts $5B in 2023 Covid vaccine sales, reports net income loss and cost increases

3 years ago

First page Previous page 97 98 99100101 102 103 Next page Last page